NPS-2143 (also called SB262470; NPS-2143; SB-262470; NPS 2143; SB-262470A) is a potent and selective antagonist of calcium-sensing receptor (CaSR) with the potential to be used for the treatment of osteoporosis.

Etelcalcetide (formerly known as AMG-416, KAI-4169; ONO5163; velcalcetide, trade name Parsabiv) is an FDA approved calcimimetic drug for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) patients undergoing hemodialysis.

Etelcalcetide HCl (formerly known as ONO-5163; AMG-416, KAI-4169 and velcalcetide, Parsabiv), the hydrochloride salt of Etelcalcetide, is an agonist of calcium-sensing receptor that has been approved by FDA in 2017 as a calcimimetic drug for the treatment of secondary hyperparathyroidism in CKD (chronic kidney disease) patients undergoing hemodialysis.

Cinacalcet (also known as AMG-073; trade names Sensipar, Mimpara) is a calcimimetic that mimics the action of calcium on tissues by allosteric activation of the calcium-sensing receptor expressed in various human organ tissues.

Tecalcet (KRN-568; NPS-R-568; R-568) is a novel, potent, orally bioactive calcimimetic compound/calcium channel agonist that can be potentially used for the treatment of hyperparathyroidism, postmenopausal symptom.

Strontium Ranelate (S-12911; Distrontium renelate; Protelos or Protos) is an approved antiosteoporotic drug in EU, it can also slow the course of osteoarthritis of the knee by both increasing bone formation and reducing bone resorption, leading to a rebalance of bone turnover in favor of bone formation.

Cinacalcet HCl (also known as AMG-073; KRN1493; KRN-1493; Regpara; trade names Sensipar, Mimpara), the hydrochloride salt of Cinacalcet, is a calcimimetic that mimics the action of calcium on tissues by allosteric activation of the calcium-sensing receptor expressed in various human organ tissues.

NPS-2143 HCl (also known as SB-262470 and SB-262470A) is a novel, potent and selective antagonist of calcium-sensing receptor (CaSR) with IC50 of 43 nM.